
Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis
Keywords: Crohn's Disease; Fcγ Receptor; Drug Modification; Mouse Model; ADA; adalimumab; ADAâÎF; hypo-fucosylated ADA; ADCC; antibody-dependent cellular cytotoxicity; FcγR; Fcγ-receptors; IBD; inflammatory bowel disease; IFNγ; interferon γ; Ig; immunoglo